What is BIIB's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 34.56B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for BIIB?

P/E (TTM) is 42.27 and 52-week range is $138.00 to $240.99 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s BIIB figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for BIIB?

The company profile lists revenue (TTM) near $9.96B, net income (TTM) near $829M, EPS (TTM) near $5.65 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Biogen Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Cambridge, Massachusetts, US, 147.8M shares outstanding, ISIN US09062X1037 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Free AI scores & summaries library

Biogen Inc

$BIIB

Health Care · Biotechnology

IR Run Scenarios

$232.65

-1.15%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 7,500 full-time employees. The firm is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. The company operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). The company is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. The company also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).

Employees

7,500

Website

www.biogen.com/

IPO

1991-09-17

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)